About Complete Genomics (NASDAQ:GNOM)
Complete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center. Its customers include some of the global academic and government research centers and biopharmaceutical companies. Effective March 18, 2013, BGI-Shenzhen announced that through its wholly-owned subsidiary, Beta Acquisition Corporation, it has completed the acquisition of the Company.
Industry, Sector and Symbol
Industry Medical Software & Technology Services
Trailing P/E Ratio-1.33617021276596
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Complete Genomics (NASDAQ:GNOM) Frequently Asked Questions
What is Complete Genomics' stock symbol?
Complete Genomics trades on the NASDAQ under the ticker symbol "GNOM."
Who are some of Complete Genomics' key competitors?
Some companies that are related to Complete Genomics include EndoChoice (GI), NAPEC (NPC), Mereo BioPharma Group (MPH), Ampio Pharmaceuticals (AMPE), Cannabis Science (CBIS), Palatin Technologies (PTN), ImmuPharma (IMM), Verona Pharma (VRP), Merus Labs International (MSLI), Dimension Therapeutics (DMTX), Allergy Therapeutics (AGY), Alliance HealthCare Services (AIQ), Summit Therapeutics (SUMM), Silence Therapeutics (SLN), Trivascular Technologies (TRIV), Bioventix (BVXP), Sinclair Pharma (SPH) and Ekf Diagnostics (EKF).
Has Complete Genomics been receiving favorable news coverage?
News coverage about GNOM stock has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Complete Genomics earned a news sentiment score of 0.12 on Accern's scale. They also gave media headlines about the company an impact score of 45.41 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of Complete Genomics?
Shares of GNOM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Complete Genomics' stock price today?
One share of GNOM stock can currently be purchased for approximately $3.14.
How big of a company is Complete Genomics?
Complete Genomics has a market capitalization of $108.29 million.
How can I contact Complete Genomics?
Complete Genomics' mailing address is 2071 Stierlin Ct, MOUNTAIN VIEW, CA 94043-4655, United States. The company can be reached via phone at +1-650-9432800.
MarketBeat Community Rating for Complete Genomics (GNOM)MarketBeat's community ratings are surveys of what our community members think about Complete Genomics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Complete Genomics (NASDAQ:GNOM) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Complete Genomics (NASDAQ:GNOM) Earnings History and Estimates Chart
Complete Genomics (NASDAQ GNOM) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/9/2012||Q312||($0.52)||($0.52)||$8.05 million||$7.27 million||View||N/A|
Complete Genomics (NASDAQ:GNOM) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Complete Genomics (NASDAQ:GNOM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Complete Genomics (NASDAQ GNOM)
No insider trades for this company have been tracked by MarketBeat.com
Complete Genomics (NASDAQ GNOM) News Headlines
Complete Genomics (NASDAQ:GNOM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Complete Genomics (NASDAQ:GNOM) Income Statement, Balance Sheet and Cash Flow Statement
Complete Genomics (NASDAQ GNOM) Stock Chart for Thursday, March, 22, 2018